Physician profile
Rincy Thomas
NPI 1588381024
$1,591.90
in general payments reported to CMS, 2019-2025
21 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $129 · 2024: $477 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $268.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $166.89 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $154.40 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbott Laboratories | $131.00 | 2023-2025 | Freestyle Libre |
| Pfizer INC. | $124.17 | 2024-2025 | |
| Amgen INC. | $103.26 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $98.99 | 2024-2025 | |
| Astellas Pharma US INC | $82.59 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $80.83 | 2025 | Airsupra, Farxiga |
| Insmed, INC. | $76.07 | 2025 | Brinsupri, Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $65.86 | 2024 | |
| Dexcom, INC. | $34.56 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $31.19 | 2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $25.92 | 2025 | |
| Esperion Therapeutics, INC. | $24.77 | 2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.19 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $23.03 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $20.00 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $19.62 | 2025 | Keveyis |
| Shield Therapeutics INC | $18.62 | 2024 | |
| Ibsa Pharma INC. | $17.50 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rincy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.